JAMES B. LEE, M.D.; JOHN C. MCGIFF, M.D.; HARTMUT KANNEGIESSER, M.D.; YAVUZ Y. AYKENT, M.D.; J. GERARD MUDD, M.D.; THOMAS F. FRAWLEY, M.D.
Prostaglandin A1 (PGA1) was infused intravenously for 1 hr into six patients with fixed diastolic essential hypertension. Low infusion rates (0.1 to 2.1 µg/kg body weight per min) were not associated with a change in blood pressure but resulted in a significant increase in effective renal plasma flow (ERPF), glomerular filtration rate (GFR), urinary flow, and urinary sodium and potassium excretion. At higher infusion rates (2.1 to 11.2 µg/kg body weight per min) the blood pressure fell from a mean control of 200/112 mm Hg to 140/85 mm Hg. This was associated with a reduction in previously elevated ERPF, GFR, urinary flow, and sodium and potassium excretions to or toward preinfusion levels. Thus, decreased renal perfusion secondary to a reduction in systemic arterial pressure offset the direct renal vasodilating and natriuretic action of PGA1. The net result was that normotension induced by PGA1 in hypertensive patients was associated with a normal renal blood flow and a normal sodium excretion.
LEE JB, MCGIFF JC, KANNEGIESSER H, AYKENT YY, MUDD JG, FRAWLEY TF. Prostaglandin A1: Antihypertensive and Renal Effects: Studies in Patients with Essential Hypertension. Ann Intern Med. ;74:703–710. doi: 10.7326/0003-4819-74-5-703
Download citation file:
Published: Ann Intern Med. 1971;74(5):703-710.
Cardiology, Coronary Risk Factors, Hypertension, Nephrology.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use